{"generic":"Florbetapir F-18","drugs":["Amyvid","Florbetapir F-18"],"mono":{"0":{"id":"930188-s-0","title":"Generic Names","mono":"Florbetapir F-18"},"1":{"id":"930188-s-1","title":"Dosing and Indications","sub":{"0":{"id":"930188-s-1-4","title":"Adult Dosing","mono":"<b>PET brain study, To estimate beta-amyloid neuritic plaque density in patients with cognitive impairment:<\/b> 370 megabecquerels (10 millicuries) IV single bolus in 10 mL or less total volume (MAX 50 mcg mass dose); begin 10-minute PET imaging 30 to 50 minutes after IV injection "},"1":{"id":"930188-s-1-5","title":"Pediatric Dosing","mono":"not indicated for use in pediatric patients "},"3":{"id":"930188-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>PET brain study, To estimate beta-amyloid neuritic plaque density in patients with cognitive impairment<br\/>"}}},"3":{"id":"930188-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930188-s-3-9","title":"Contraindications","mono":"specific contraindications have not been determined <br\/>"},{"id":"930188-s-3-10","title":"Precautions","mono":"<ul><li>image interpretation errors, especially false negatives, have been reported; evaluate image independent of clinical information<\/li><li>radiation-emitting product; cancer risk may be increased; avoid unnecessary radiation exposure and ensure safe handling<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"930188-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"930188-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"930188-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Hypertension, Increased blood pressure<\/li><li><b>Dermatologic:<\/b>Injection site reaction (0.5%)<\/li><li><b>Gastrointestinal:<\/b>Nausea (0.6%)<\/li><li><b>Musculoskeletal:<\/b>Musculoskeletal pain (0.8%)<\/li><li><b>Neurologic:<\/b>Headache (1.8%)<\/li><li><b>Other:<\/b>Fatigue (0.6%)<\/li><\/ul>"},"6":{"id":"930188-s-6","title":"Drug Name Info","sub":{"0":{"id":"930188-s-6-17","title":"US Trade Names","mono":"Amyvid<br\/>"},"2":{"id":"930188-s-6-19","title":"Class","mono":"Diagnostic Agent, Radiopharmaceutical Imaging<br\/>"},"3":{"id":"930188-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"930188-s-7","title":"Mechanism Of Action","mono":"Florbetapir F-18 is a fluorine (18) radiolabeled solution for diagnostic imaging of beta-amyloid neuritic plaque density in the brain. Florbetapir F-18 decays by emission of positron (beta+) to 0 18, which is detectable via positron emission tomography. The main photons applicable for diagnostic imaging are the coincident pair of 511 keV gamma photons <br\/>"},"8":{"id":"930188-s-8","title":"Pharmacokinetics","sub":{"2":{"id":"930188-s-8-25","title":"Metabolism","mono":"Polar F 18 metabolites: active <br\/>"},"3":{"id":"930188-s-8-26","title":"Excretion","mono":"<ul><li>Bile: primary route<\/li><li>Fecal: primary route<\/li><li>Renal: polar metabolites<\/li><\/ul>"}}},"9":{"id":"930188-s-9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>waterproof gloves and shielding are required for proper handling of radioactive material<\/li><li>use a short IV catheter (approximately 1.5 inches or less) to minimize contrast agent adsorption<\/li><li>begin 10-minute PET imaging 30 to 50 minutes after IV injection<\/li><\/ul>"},"10":{"id":"930188-s-10","title":"Monitoring","mono":"no specific monitoring has been determined<br\/>"},"13":{"id":"930188-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise female patients who are breastfeeding to use an alternate infant nutrition source, such as stored breast milk or infant formula, for 24 hours after receiving drug.<\/li><li>Side effects may include nausea, musculoskeletal pain, headache, fatigue, increased blood pressure, and injection site reaction (eg, injection site hemorrhage, irritation, or pain).<\/li><\/ul>"}}}